Qureight analyses medical imaging for clinical trials: image management, central reads, data curation and quality control, endpoint discovery and trial read-outs. Its named deep-learning biomarkers, Lung8, Air8, Fibr8, Glass8 and Vascul8, cover pulmonary fibrosis, pulmonary hypertension and bronchiectasis.
Imaging endpoints are the bottleneck in respiratory trials. Manual central reads are slow, expensive and variable between readers, and that variability directly costs statistical power, which means more patients, more time and more money for the same answer. A consistent automated measurement reduces the noise the trial has to overcome.
It is a Cambridge company working with biopharmaceutical sponsors, not a product anyone signs up for, so nothing is priced publicly. Imaging biomarkers need regulatory acceptance for each specific context of use, and its focus on lung and cardiac disease is narrow by design.
